Gene targeting is a technique used in molecular genetics to disrupt or modify the expression or function of a specific gene. It involves introducing a modified gene into an organism, so that the organism's genome is modified in a specific way. This technique is used to study gene function and is also a key component of gene therapy.

Gene Target Solutions has a flexibleconsultative approach in dealing with all our scientists’ pre-sales and after sales requirements. Our broad portfolio of leading-edge sequencing and array-based solutionsqPCR technologiesDNA/RNA fragment analysisaddress a range of genomic complexity and throughputs. 'we pride ourselves on the level of interest we take in learning about our client’s direction and the implications of those problems'

Cellomics technology LLC is a biotechnology company located at the biotech corridor in Maryland. Our vision is to become a leading provider of products and services for gene targeting in mammalian cells. We are dedicated to develop innovative tools for genetic engineering somatic and stem cells, and provides professional and licensed services .

Xueji Bio is a new cell therapy company founded by returnee experts to regenerate hematopoietic lineages (including blood cells and immune cells) in vitro, with unique stem cell reprogramming, editing and differentiation technologies. The company's unique iPSC establishment technology and gene targeting technology can quickly establish a platform using platelet cells as a drug delivery carrier.

Gene Logic is a leading integrated genomics company providing comprehensive Genomic Reference Databases and GLP compliant Microarray Services. Over 2/3rd of the top 25 Pharma companies, leading research institutes and emerging biotech companies worldwide have chosen us as their preferred genomics partner and utilize our expertise for understanding underlying mechanisms of diseases, discovery and prioritization of gene targets & biomarkers.

Rex is on a mission to bring animal health to the 21st century by making veterinary medicine and husbandry data driven.
They believe that data has the power to transform the animal health industry as it has transformed the fields of finance, weather, and human health. By bringing together data from various sources and time periods, the insights they produce can reshape: 1) the way pharmaceutical companies discovers new gene targets and develops drugs, 2) the way veterinarians manage chronic diseases in animals, and 3) the way the community understands and perceives animal health.



Cambridge Cell Networks is delivers services solutions to the research community in the biotechnology industry.  With a strong expertise in systems toxicology, the company develops tools for scientists who need to better understand on- and- off target mechanisms of action of compounds and the links between genes, targets, chemicals and pathologies.
Their flagship products are toxicology ontologies, databases and analytical software. Their databases comprise decades of expert curation of scientific literature and capture information about a range of  toxic endpoints, chemical structure information (covering all known drugs and tool compounds) with protein and gene targets, toxicology relevant signalling pathways etc.

Ocimum Biosolutions is a leading integrated global genomics company providing GLP-compliant microarray services, comprehensive genomic reference databases, life science lab information management solutions and essential research consumables. Majority of the top 25 pharmaceutical companies, leading research institutes and emerging biotech companies worldwide have chosen us as their preferred outsourcing partner and utilize our expertise for understanding underlying mechanisms of diseases, discovery and prioritization of gene targets and biomarkers. There solutions span across key priority areas including BioPharmaceutical, Diagnostics, Agriculture, Food & Nutrition. Diverse research and development efforts in such key areas have benefited from our unique range of integrated services.

TargetGene was founded in 2012 by drs. Dan Weinthal and Yoel Shiboleth. They invented RNA-guided nucleases for genome editing in 2011. Their patent has recently been granted in the US following grants in many other jurisdictions .

Leadership board members include former pfizer executive and 30 under 30 in healthcare by Forbes. Scientific advisory board includes darrell Irvine, PhD, director of the Koch institute for cancer research, and MIT professor breaking new ground in gene targeting strategies for cancer. Previous board member roles include leading Intellia as CFO through their IPO .

Cure First was founded with the mission to support innovation in cancer research. Its work has led to important publications that indicate new drug regimens for patients whose cancers show specific mutations or for patients with certain genetic predispositions. Most cancer-targeted drugs that the research findings indicated are only approved for certain cancer types and thus difficult to obtain for doctors in treating other cancers because of lack of insurance reimbursement .

Search and
explore companies

Gene Targeting

For more optimized search results,
use multiple english keywords and apply filters

Search and explore companies

Company size

Location